Location History:
- Boston, MA (US) (2003)
- Houaton, TX (US) (2012)
- Brookline, MA (US) (2012 - 2017)
- Houston, TX (US) (2016 - 2019)
Company Filing History:
10 out of 1,216 
2 out of 839 
2 out of 5,506 
Years Active: 2003-2019
Title: The Innovative Contributions of Ronald A. DePinho
Introduction
Ronald A. DePinho is a prominent inventor based in Houston, Texas, known for his significant contributions to cancer research and treatment. With a total of 12 patents to his name, he has made remarkable strides in the field of oncology, particularly in identifying biomarkers and developing therapeutic methods.
Latest Patents
Among his latest patents is the invention of the ZNF365/ZFP365 biomarker, which is predictive of anti-cancer response. This invention is based on the identification of novel biomarkers that can help predict how patients will respond to anti-cancer therapies. Another notable patent involves enolase inhibitors and methods of treatment therewith. This patent provides compounds that inhibit enolase enzymes, including the preferential inhibition of one isoenzyme over others. These compounds can be utilized in various treatment methods, along with pharmaceutical compositions.
Career Highlights
Throughout his career, Ronald A. DePinho has worked with esteemed institutions such as the Dana-Farber Cancer Institute and the University of Arkansas. His work has been pivotal in advancing cancer research and developing innovative treatment options.
Collaborations
He has collaborated with notable colleagues, including Lynda Chin and Giovanni Tonon, contributing to a rich environment of research and innovation in cancer therapies.
Conclusion
Ronald A. DePinho's work exemplifies the impact of innovation in the medical field, particularly in cancer research. His patents and collaborations continue to influence the development of effective treatments for patients.